Sutherland L R, Martin F
Department of Gastroenterology, University of Calgary, Canada.
Dig Dis Sci. 1987 Dec;32(12 Suppl):64S-66S. doi: 10.1007/BF01312466.
The efficacy and safety of 4 g 5-aminosalicylic acid (5-ASA) enemas were assessed in 59 patients with ulcerative colitis involving up to 50 cm of their distal colon. Twenty-nine patients received 5-ASA and 30 received a placebo. There were 12 dropouts (five in the active and seven in the placebo group) during the study because of insufficient efficacy. After six weeks of therapy, 63% of the patients receiving the 5-ASA were considered to be "much improved" by the study physician compared to 20% patients on placebo (P less than 0.0001). A disease activity index (DAI), based upon patient symptoms and sigmoidoscopic appearance, was used to assess efficacy. Mean DAI declined 75% for patients on 5-ASA enemas and 32% for patients on placebo (P less than 0.05). The 5-ASA enemas are well tolerated and are of benefit in the treatment of ulcerative colitis confined to the distal colon.
对59例远端结肠受累达50厘米的溃疡性结肠炎患者评估了4克5-氨基水杨酸（5-ASA）灌肠剂的疗效和安全性。29例患者接受5-ASA治疗，30例接受安慰剂治疗。研究期间，因疗效不佳有12例退出研究（5例在活性药物组，7例在安慰剂组）。治疗六周后，研究医生认为接受5-ASA治疗的患者中有63%“改善明显”，而接受安慰剂治疗的患者中这一比例为20%（P<0.0001）。基于患者症状和乙状结肠镜检查表现的疾病活动指数（DAI）用于评估疗效。接受5-ASA灌肠剂治疗的患者平均DAI下降75%，接受安慰剂治疗的患者平均DAI下降32%（P<0.05）。5-ASA灌肠剂耐受性良好，对局限于远端结肠的溃疡性结肠炎治疗有益。
